Drilldown: Medicines

None (2) · Sodium fluoride (1)

Emgality (1) · Many; topical professional/OTC and Rx oral (1) · Vyepti (1)

Anti-CGRP ligand monoclonal antibody (2) · [[:Category:Anticaries_agents|Anticaries agent]] (1) · [[:Category:Trace_elements|Trace element]] (1)

None (1) · Humanized IgG1 monoclonal antibody binding CGRP peptide; IV infusion enables fastest onset of any CGRP mAb (1) · Humanized IgG4 monoclonal antibody binding CGRP peptide; prevents CGRP from activating its receptor (1)

Preventive treatment of migraine in adults (1) · Preventive treatment of migraine in adults; episodic cluster headache (1) · '"`UNIQ--vote-0000131A-QINU`"', '"`UNIQ--vote-0000131B-QINU`"' (1)

100 mg IV every 3 months; may increase to 300 mg IV every 3 months (1) · Migraine: 240 mg SC loading dose, then 120 mg SC monthly. Cluster: 300 mg SC at onset of cluster period, then monthly during cluster. (1) · OTC dentifrice/rinse 0.05-0.5% fluoride daily; Rx 1.1% sodium fluoride toothpaste/gel daily; supplements (where local water non-fluoridated) age-titrated 0.25-1 mg/d (1)

100 mg/mL vial for IV infusion (1) · 120 mg/mL prefilled syringe or autoinjector (1) · Toothpaste, rinse, gel, varnish (topical); 0.25, 0.5, 1 mg tablets and drops (Rx supplements where appropriate) (1)

240 mg loading + 120 mg/month for migraine; 300 mg/month for cluster (1) · 300 mg/quarter (1) · Topical: per formulation; oral supplement age-dependent (1)

Intravenous infusion (1) · oral (1) · Subcutaneous (1) · Topical (1)

Caries reduction over months to years of consistent use (1) · Effect demonstrated within 24 hours in some patients (1) · Over weeks (1)

3-month dosing interval (1) · Hours per topical application (1) · Monthly dosing (1)

None · ~12 hours · ~27 days · ~5 h (caffeine) · '''Autoinduction''': 25-65 hours initially, falling to 12-17 hours after 2-3 weeks of dosing as carbamazepine induces its own CYP3A4 metabolism. Major clinical implication: doses require re-titration after the autoinduction period'"`UNIQ--ref-0000001D-QINU`"' · 0.5-1.5 hours (plasma); pharmacodynamic effect persists 24+ hours'"`UNIQ--ref-000000DE-QINU`"' · 1-1.3 hours'"`UNIQ--ref-000001A1-QINU`"' · 1-1.5 hours'"`UNIQ--ref-00000DE3-QINU`"' · 1-2 hours (parent compound)'"`UNIQ--ref-00000029-QINU`"' · 1-2 hours (parent); 18-30 hours for active metabolite oxypurinol'"`UNIQ--ref-0000030F-QINU`"' · 1-2 hours'"`UNIQ--ref-00000017-QINU`"' · 1-3 hours (normal liver); markedly prolonged in overdose with glutathione depletion'"`UNIQ--ref-000006A5-QINU`"' · 1-3 minutes (very short)'"`UNIQ--ref-00000C0F-QINU`"' · 1.4 hours (parent); 13-24 hours for active metabolite canrenone'"`UNIQ--ref-00000354-QINU`"' · 1.5-2 hours (longer in renal failure)'"`UNIQ--ref-00000222-QINU`"' · 1.5-2 hours'"`UNIQ--ref-00000020-QINU`"' · 10-11 hours (benazeprilat, the active metabolite)'"`UNIQ--ref-00000A22-QINU`"' · 11-13 h (immediate-release); 11-16 h (extended-release) · 11-15 hours'"`UNIQ--ref-00000842-QINU`"' · 12-15 hours (intermediate); '''no active metabolites''' (key clinical feature)'"`UNIQ--ref-00000023-QINU`"'

Other values:

Search

100% (IV) (1) · Not formally established (high SC) (1) · Topical: local effect on enamel; systemic supplementation has high oral bioavailability with skeletal accumulation (1)

Limited data; avoid (2) · Safe at routine fluoride levels.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1)

OTC (most dentifrice and rinse) and [[USLegal:Prescription only|Rx-only]] (high-concentration paste/gel, supplements) in US (1) · Rx (2)